

**January 10th, 2012**  
**Announcement no. 01**

### **Announcement from major shareholder**

---

BioPorto A/S has been informed that T. Bernt Nielsen A/S and associates have reduced their ownership below 5% of the share capital in BioPorto A/S.

#### **Further details:**

Frank Harder, CFO  
Tel: +45 4529 0000  
E-mail: [investor@bioporto.com](mailto:investor@bioporto.com)

#### **About BioPorto**

*BioPorto develops and markets antibodies and antibody-based products, including assays for the diagnosis of diseases—for the benefit of individual patients and the effectiveness of the healthcare sector. The company has inter alia developed a method (NGAL) for the diagnosis and monitoring of acute renal injury. Within the focus areas of the company, it is BioPorto's strategy to develop new methods that can be protected by patents and used extensively in the diagnosis of a number of diseases. BioPorto was established in 2000 and has approx. 30 employees. The Company's shares are listed on the NASDAQ OMX in Copenhagen (symbol BIOPOR).*